Status and phase
Conditions
Treatments
About
Nautralsitic, Open-label, Single Arm, Uncontrolled Study Evaluating the Effects of Long Acting Injectable (LAI) on Phychosocial Functioning Congitive Functioning and Patient Reported Acceptability of Treatment 'Reported Acceptability of Treatment' Regarding Quality of Life Subjective Well-being Under Neuroleptic Medication in Schizophrenia Patients
Full description
Primary Objective
To evaluate the efficacy of aripiprazole long acting injectable form in Turkish patients with schizophrenia on psychosocial functioning, quality of life and patient reported acceptability of treatment. Secondary Objective(s) To evaluate the cognitive functioning of the patients To evaluate positive and negative symptoms of the Aripiprazole Long Acting Injectable (LAI), To evaluate adherence of Aripiprazole Long Acting Injectable (LAI) treatment, To evaluate tolerability of Aripiprazole Long Acting Injectable (LAI).
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
23 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal